Georgios Schoretsanitis, Dr

  • 5Articles
  • 70.2KReads
  • 2018–2023Active
  • 34Collaborators
  • 230Citations

About

Dr. Georgios Schoretsanitis is affiliated with the Department of Psychiatry, Psychotherapy and Psychosomatics at the University of Zurich and with Northwell Health's Zucker Hillside Hospital and Zucker School of Medicine. His publications from 2018 to 2023 focus on therapeutic drug monitoring in psychiatry, specifically addressing antipsychotic treatments for schizophrenia and schizoaffective disorders, including olanzapine and clozapine management. He has also contributed to research on neuroleptic malignant syndrome outcomes and dosing strategies for duloxetine in different patient populations. His work often intersects with patient care optimization in major depressive disorder and psychopharmacology.

Publications

JCP
Therapeutic Reference Range for Olanzapine
Systematic Review

Therapeutic Reference Range for Olanzapine

July 19, 2023

A therapeutic reference range of 20–40 ng/mL for oral and long-acting injectable olanzapine yields optimal treatment effects in schizophrenia spectrum disorders. Dose reduction is not needed above 40 ng/mL...
, , , et al
JCP
Best Practices for Switching to Clozapine in Patients With Schizophrenia
ASCP Corner

Best Practices for Switching to Clozapine in Patients With Schizophrenia

July 4, 2022

This article provides expert advice on dosage and timing when switching from a prior medication to clozapine in patients with schizophrenia.
,
JCP
Review Article

Outcomes of NMS With Depot Versus Oral Antipsychotics

November 24, 2020

Is the advantage of longer-term medication release with long-acting injectable antipsychotics offset by an increased risk of more prolonged and severe neuroleptic malignant syndrome? This systematic review and pooled...
, , , et al
JCP
Consensus Statement

Consensus on Monitoring Blood Antipsychotic Levels

May 19, 2020

The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this...
, , , et al
JCP
Original Research

Duloxetine Dosing Strategies and Smoking Status

September 4, 2018

Cigarette smoking is common among individuals depression, and smoking can affect the metabolism of antidepressant medications. Read this article to learn dosing strategies that physicians can employ when treating...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe